Literature DB >> 8476220

An analysis of vincristine-resistance in BHK cells pretreated with 1-beta-D-arabinofuranosylcytosine.

Y Chen1, B Goz, L Kirkman.   

Abstract

As with SV40-transformed BHK cells (1), pretreatment of BHK cells with 1-beta-D-arabinofuranosylcytosine (araC) very markedly enhanced the resistance frequency to N-phosphonoacetyl-L-aspartate (PALA) but only modestly increased the resistance frequency to vincristine (VCR). AraC pretreatment of cells that already had moderate VCR-resistance again only modestly enhanced the resistance frequency at a higher VCR concentration. By contrast, delaying the addition of VCR to BHK cells by 7-24 hours after pretreatment with araC increased the enhancement of VCR-resistance frequency to a level comparable to the enhancement of PALA-resistance frequency. VCR-resistant clones isolated without or after araC pretreatment were analysed for amplification of the multidrug resistance (mdr) gene. One of four clones isolated by single-step selection with no araC pretreatment and four of six clones isolated after araC pretreatment showed amplification of the mdr gene. All VCR-resistant clones tested were cross-resistant to actinomycin D and VCR-resistance was inhibited by treatment with verapamil.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476220

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage.

Authors:  T G Paulson; A Almasan; L L Brody; G M Wahl
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

2.  Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.

Authors:  Kefeng Lei; Ran Sun; Lee H Chen; Bill H Diplas; Casey J Moure; Wenzhe Wang; Landon J Hansen; Yulei Tao; Xufeng Chen; Chin-Pu Jason Chen; Paula K Greer; Fangping Zhao; Hai Yan; Darell D Bigner; Jiaoti Huang; Yiping He
Journal:  Sci Rep       Date:  2018-08-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.